494 related articles for article (PubMed ID: 35790708)
1. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.
Hayes LR; Kalab P
Neurotherapeutics; 2022 Jul; 19(4):1061-1084. PubMed ID: 35790708
[TBL] [Abstract][Full Text] [Related]
2. Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia.
Jovičić A; Paul JW; Gitler AD
J Neurochem; 2016 Aug; 138 Suppl 1():134-44. PubMed ID: 27087014
[TBL] [Abstract][Full Text] [Related]
3. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets.
Scotter EL; Chen HJ; Shaw CE
Neurotherapeutics; 2015 Apr; 12(2):352-63. PubMed ID: 25652699
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of cryptic splicing associated with TDP-43 depletion.
Humphrey J; Emmett W; Fratta P; Isaacs AM; Plagnol V
BMC Med Genomics; 2017 May; 10(1):38. PubMed ID: 28549443
[TBL] [Abstract][Full Text] [Related]
5. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis?
Vanden Broeck L; Callaerts P; Dermaut B
Trends Mol Med; 2014 Feb; 20(2):66-71. PubMed ID: 24355761
[TBL] [Abstract][Full Text] [Related]
6. The era of cryptic exons: implications for ALS-FTD.
Mehta PR; Brown AL; Ward ME; Fratta P
Mol Neurodegener; 2023 Mar; 18(1):16. PubMed ID: 36922834
[TBL] [Abstract][Full Text] [Related]
7. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43.
Mann JR; Gleixner AM; Mauna JC; Gomes E; DeChellis-Marks MR; Needham PG; Copley KE; Hurtle B; Portz B; Pyles NJ; Guo L; Calder CB; Wills ZP; Pandey UB; Kofler JK; Brodsky JL; Thathiah A; Shorter J; Donnelly CJ
Neuron; 2019 Apr; 102(2):321-338.e8. PubMed ID: 30826182
[TBL] [Abstract][Full Text] [Related]
8. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD.
Kumar S; Phaneuf D; Cordeau P; Boutej H; Kriz J; Julien JP
Mol Neurodegener; 2021 Jan; 16(1):1. PubMed ID: 33413517
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of TDP-43 Proteinopathy Onset and Propagation.
Chen HJ; Mitchell JC
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199367
[TBL] [Abstract][Full Text] [Related]
10. TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia.
Sidibé H; Khalfallah Y; Xiao S; Gómez NB; Fakim H; Tank EMH; Di Tomasso G; Bareke E; Aulas A; McKeever PM; Melamed Z; Destroimaisons L; Deshaies JE; Zinman L; Parker JA; Legault P; Tétreault M; Barmada SJ; Robertson J; Vande Velde C
Brain; 2021 Dec; 144(11):3461-3476. PubMed ID: 34115105
[TBL] [Abstract][Full Text] [Related]
11. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.
Ratti A; Buratti E
J Neurochem; 2016 Aug; 138 Suppl 1():95-111. PubMed ID: 27015757
[TBL] [Abstract][Full Text] [Related]
12. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD.
Ling JP; Pletnikova O; Troncoso JC; Wong PC
Science; 2015 Aug; 349(6248):650-5. PubMed ID: 26250685
[TBL] [Abstract][Full Text] [Related]
13. Cracking the cryptic code in amyotrophic lateral sclerosis and frontotemporal dementia: Towards therapeutic targets and biomarkers.
Akiyama T; Koike Y; Petrucelli L; Gitler AD
Clin Transl Med; 2022 May; 12(5):e818. PubMed ID: 35567447
[TBL] [Abstract][Full Text] [Related]
14. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy.
Chew J; Cook C; Gendron TF; Jansen-West K; Del Rosso G; Daughrity LM; Castanedes-Casey M; Kurti A; Stankowski JN; Disney MD; Rothstein JD; Dickson DW; Fryer JD; Zhang YJ; Petrucelli L
Mol Neurodegener; 2019 Feb; 14(1):9. PubMed ID: 30767771
[TBL] [Abstract][Full Text] [Related]
15. TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.
Montalbano M; McAllen S; Cascio FL; Sengupta U; Garcia S; Bhatt N; Ellsworth A; Heidelman EA; Johnson OD; Doskocil S; Kayed R
Neurobiol Dis; 2020 Dec; 146():105130. PubMed ID: 33065281
[TBL] [Abstract][Full Text] [Related]
16. TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration.
Gao J; Wang L; Yan T; Perry G; Wang X
Mol Cell Neurosci; 2019 Oct; 100():103396. PubMed ID: 31445085
[TBL] [Abstract][Full Text] [Related]
17. Family-based exome sequencing identifies RBM45 as a possible candidate gene for frontotemporal dementia and amyotrophic lateral sclerosis.
van der Zee J; Dillen L; Baradaran-Heravi Y; Gossye H; Koçoğlu C; Cuyt I; Dermaut B; Sieben A; Baets J; De Jonghe P; Vandenberghe R; De Deyn P; Cras P; Engelborghs S; Van Broeckhoven C;
Neurobiol Dis; 2021 Aug; 156():105421. PubMed ID: 34118419
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of
Baughn MW; Melamed Z; López-Erauskin J; Beccari MS; Ling K; Zuberi A; Presa M; Gonzalo-Gil E; Maimon R; Vazquez-Sanchez S; Chaturvedi S; Bravo-Hernández M; Taupin V; Moore S; Artates JW; Acks E; Ndayambaje IS; Agra de Almeida Quadros AR; Jafar-Nejad P; Rigo F; Bennett CF; Lutz C; Lagier-Tourenne C; Cleveland DW
Science; 2023 Mar; 379(6637):1140-1149. PubMed ID: 36927019
[TBL] [Abstract][Full Text] [Related]
19. Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia.
Pasetto L; Grassano M; Pozzi S; Luotti S; Sammali E; Migazzi A; Basso M; Spagnolli G; Biasini E; Micotti E; Cerovic M; Carli M; Forloni G; De Marco G; Manera U; Moglia C; Mora G; Traynor BJ; Chiò A; Calvo A; Bonetto V
Brain; 2021 Dec; 144(12):3710-3726. PubMed ID: 34972208
[TBL] [Abstract][Full Text] [Related]
20. TDP-43 pathology: From noxious assembly to therapeutic removal.
Keating SS; San Gil R; Swanson MEV; Scotter EL; Walker AK
Prog Neurobiol; 2022 Apr; 211():102229. PubMed ID: 35101542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
